ANAPLASTIC LARGE CELL LYMPHOMA, ALK-POSITIVE
Clinical trials for ANAPLASTIC LARGE CELL LYMPHOMA, ALK-POSITIVE explained in plain language.
Never miss a new study
Get alerted when new ANAPLASTIC LARGE CELL LYMPHOMA, ALK-POSITIVE trials appear
Sign up with your email to follow new studies for ANAPLASTIC LARGE CELL LYMPHOMA, ALK-POSITIVE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for rare lymphoma: lorlatinib trial targets Drug-Resistant cancers
Disease control CompletedThis phase 2 trial tested the oral drug lorlatinib in 9 people with ALK-positive anaplastic large cell lymphoma whose cancer had returned or stopped responding to previous ALK inhibitors. The main goal was to see how many patients' tumors shrank or disappeared. Researchers also t…
Matched conditions: ANAPLASTIC LARGE CELL LYMPHOMA, ALK-POSITIVE
Phase: PHASE2 • Sponsor: University of Milano Bicocca • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New cocktail targets tough lymphomas
Disease control CompletedThis early-phase study tested a combination of three drugs (VIP152, venetoclax, and prednisone) in 8 adults with aggressive non-Hodgkin lymphomas that had returned or not responded to prior treatments. The main goals were to check safety and find the best dose, while also measuri…
Matched conditions: ANAPLASTIC LARGE CELL LYMPHOMA, ALK-POSITIVE
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC